Research / Pre-Clinical · Patent-Filed
Aurum Supercell
A universal programmable cell platform. Cleanse | Repair | Regenerate | Replace. Lead research application: Type 1 Diabetes.
What It Is
Most cell therapies are dumb delivery vehicles. Aurum Supercell cells think. A four-layer architecture — chassis, cloak, payload, brain — programs any therapeutic cell to find its target, evade immune destruction, deliver its payload, and decide autonomously when to act. Trigger mechanisms are modular: bioelectric induction, DNA-encoded protein keys, chemical gradients, pH/temperature response, optogenetic activation, CRISPR gene switches. Swap the trigger, change the target — same chassis underneath.
Chassis — reprogrammed O-negative blood cell, universal patient-neutral carrier. Cloak — patient-matched HLA markers + metabolic mimicry render the agent invisible to immune detection. Payload — six programmable behavioral modes: Defend (converts rogue T-cells to regulatory T-cells), Repair (epigenetic rewrite restoring gene expression), Clone (controlled cell replication), Convert (transdifferentiation between cell types), Reset (clears immune debris), Deliver (precision payload carrier). Brain — autonomous decision logic, activates only on verified target signature.
Lead research application: Type 1 Diabetes beta cell reactivation with permanent bone marrow upgrade — one treatment, lifetime protection. Platform roadmap extends to CAR-T cancer variants, autoimmune regulation, blood-brain barrier crossing for Alzheimer's, organ rejection prevention, and regenerative wound healing.
Stage
Research / Pre-Clinical. Computational design and simulation platform. NSF Phase I grant application in preparation. No in-vivo or wet-lab testing has been conducted. All evidence below is in-silico (computational) modeling output from the Aurum Sphere agent swarm.
Computational Modeling Validation (in silico, not wet-lab)
The Aurum Sphere swarm runs the Aurum Supercell biological model continuously. Live telemetry as of 2026-05-02:
| T1D-core domains | medicine + supercell — added 2026-04-29, evolving in lockstep |
| Combined cycles | 567,998 — continuous evolution since 2026-04-29 |
| Agent reproductions | 39,323,638 births |
| Influential agents | 6,707,923 |
| Domain weight | Both saturated at peak 60.00 |
| Wider T1D footprint | 16,530,864 cycles across 11 supporting domains (biology, genomics, biochemistry, proteomics, behavioral_science, peripheral neuropathy senses) |
This is computational simulation evidence. It is not a substitute for wet-lab or in-vivo validation. NSF Phase I funding is targeted to engage a dedicated biochemist/clinical researcher to advance the platform from simulation to in-vivo validation.
Patents (Provisional — USPTO)
- 020 — Porous functional replacement beta cell architecture
- 021 — CRISPR-core DNA repair agent
- 026 — Universal biological agent template
- 036 — Blood cell reprogramming + permanent bone marrow upgrade
- 042 — Natural cell division triggering protocol
- 069 — Real-time CGM AI dosing
- 111 — Unified voxel-agent simulation framework
- 112 — Bioelectric-addressed cell state transition for pancreatic beta cell reactivation — core patent
- 126 — Metabolic-masking cellular delivery system: O-negative universal donor pathway + patient-matched immune cloak
All patents are provisional filings through Aurum Nebula LLC (USPTO 64/015,796 · 64/040,076 · 64/045,177). Provisional → utility conversion deadline: March 2027.
Peer-Reviewed Backing
- Alpha-to-beta transdifferentiation confirmed in human islets — bioRxiv Feb 2025, 650,000 cells, 121 donors. First direct human lineage tracing evidence.
- PDX1 + MafA AAV delivery normalized blood glucose in autoimmune NOD mice — Nature 2019, Furuyama et al.
- Dnmt1 + Arx double knockout → extensive alpha-to-beta conversion with confirmed GSIS — Cell Metabolism 2017.
- Spontaneous alpha-to-beta conversion after >99% beta cell ablation — Nature 2010, Thorel et al.
- FoxP3 CNS2 demethylation → permanent Treg commitment — established mechanism.
Technology Stack
| BioNeMo | Biological simulation engine — flagship NVIDIA biotech alignment |
| DGX H200 | 2B-agent voxel simulation at single-cell islet resolution |
| Holoscan | Future: real-time clinical and surgical monitoring |
| Clara | FDA-friendly medical imaging path |